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Depression is common after stroke. This substantive update including new and combination interventions expands on our previous Cochrane Reviews pub-
lished in 2004 and updated in 2008.
SEARCH METHODS
We searched electronic databases from inception to 
August 2018, clinical trial registers, conference proceed-
ings, and contacted study authors.
SELECTION CRITERIA
Randomized controlled trials comparing (1) pharmaco-
logical interventions with placebo; (2) noninvasive brain 
stimulation with sham stimulation/usual care; (3) psy-
chological therapy with usual care/attention control; (4) 
pharmacological and psychological therapy with pharma-
cological intervention and usual care/attention control; 
and (5) noninvasive brain stimulation and pharmacologi-
cal intervention with pharmacological intervention and 
sham stimulation/usual care; to treat depression. Four 
comparisons are not reported because we found no trials.
RESULTS
Forty-nine trials (56 comparisons) with 3342 partici-
pants. Data were available for intervention (1) with 20 
comparisons; (2) with 8; (3) with 16; (4) with 2; and (5) 
with 10 comparisons.
We have very little confidence in the following results 
due to the methodological limitations of many of the 
included trials.
Pharmacological interventions may decrease the 
number of people with diagnosable depression (risk 
ratio [RR], 0.70 [95% CI, 0.55–0.88]; 8 trials, 1025 
participants, Figure), and with <50% reduction in 
depression scale scores at end of treatment (RR, 
0.47 [95% CI, 0.32–0.69]; 6 trials, 511 participants) 
compared with placebo. There was an increase in 
adverse events related to the central nervous system 
(RR, 1.55 [95% CI, 1.12–2.15]; 5 trials, 488 par-
ticipants) and gastrointestinal adverse events (RR, 
1.62 [95% CI, 1.19–2.19]; 4 trials, 473 participant) 
compared with placebo.
Psychological therapy may decrease the num-
ber of people with diagnosable depression at end 
of treatment (RR, 0.77 [95% CI, 0.62–0.95]; 6 tri-
als, 521 participants) with no evidence of death or 
adverse events compared with usual care/attention 
control.
There were no trials of noninvasive brain stimulation 
or combination therapies that reported the prevalence of 
diagnosable depression at end of treatment. Noninvasive 
brain stimulation interventions and combination thera-
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DISCUSSION
We lack confidence in the results for pharmaco-
logical and psychological interventions showing 
evidence of benefit and harm. The harm (in phar-
macological trials) is concerning given the small 
number of trials in which harm was recorded and 
reported.1
Large, well-designed trials, with proper collection of 
adverse events, for moderate/severe depression iden-
tified by standardized case-finding in the first 6 months 
after stroke are needed. In the absence of such tri-
als, the best clinical advice is to restrict antidepres-
sant prescription to people with persistent depression 
of moderate-severe intensity, and exercise caution in 
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Figure. Effect of pharmacotherapy versus placebo on depression at the end of treatment, grouped by method used to determine depression.
